These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26165647)

  • 21. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome.
    Chen X; Barton LF; Chi Y; Clurman BE; Roberts JM
    Mol Cell; 2007 Jun; 26(6):843-52. PubMed ID: 17588519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
    Mazzanti R; Platini F; Bottini C; Fantappiè O; Solazzo M; Tessitore L
    Biochem Pharmacol; 2009 Jul; 78(1):21-32. PubMed ID: 19447220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
    You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
    Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G2-phase arrest through p21(WAF1 / Cip1) induction and cdc2 repression by gnidimacrin in human hepatoma HLE cells.
    Yoshida M; Matsui Y; Iizuka A; Ikarashi Y
    Anticancer Res; 2009 Apr; 29(4):1349-54. PubMed ID: 19414386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand.
    Ohno T; Shirakami Y; Shimizu M; Kubota M; Sakai H; Yasuda Y; Kochi T; Tsurumi H; Moriwaki H
    Cancer Lett; 2012 Oct; 323(2):215-22. PubMed ID: 22579649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells.
    Yang H; Magilnick N; Noureddin M; Mato JM; Lu SC
    J Cell Physiol; 2007 Mar; 210(3):766-73. PubMed ID: 17154373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells.
    Wang N; Wang X; Tan HY; Li S; Tsang CM; Tsao SW; Feng Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27854312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma.
    Liu X; Zhang X; Ji L; Gu J; Zhou M; Chen S
    Oncotarget; 2015 Feb; 6(6):4226-38. PubMed ID: 25650661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM; Tseng JT; Hong DY; Huang HS
    Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner.
    Bae KM; Wang H; Jiang G; Chen MG; Lu L; Xiao L
    Cancer Res; 2007 Jul; 67(13):6053-63. PubMed ID: 17616661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation.
    Zheng QH; Ma LW; Zhu WG; Zhang ZY; Tong TJ
    J Cell Biochem; 2006 Aug; 98(5):1230-48. PubMed ID: 16514663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
    Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
    Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. siRNA-mediated knockdown of hTDE2 retards cell cycle progression through transcriptional activation of p21.
    Ren WH; Yang CY; Yang XM; Yu L
    Oncol Rep; 2014 Mar; 31(3):1314-22. PubMed ID: 24424505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
    Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
    Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
    Schmidt M; Fan Z
    Oncogene; 2001 Sep; 20(43):6164-71. PubMed ID: 11593424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of G1 cell cycle regulators in rat liver upon repeated exposure to thioacetamide.
    Kim KT; Han SY; Jeong JS
    Korean J Hepatol; 2007 Mar; 13(1):81-90. PubMed ID: 17380078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo.
    Yuan X; Sun X; Shi X; Jiang C; Yu D; Zhang W; Guan W; Zhou J; Wu Y; Qiu Y; Ding Y
    Oncol Rep; 2015 Aug; 34(2):823-32. PubMed ID: 26081192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines.
    Box AH; Demetrick DJ
    Carcinogenesis; 2004 Dec; 25(12):2325-35. PubMed ID: 15347600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
    Martinez-Becerra P; Vaquero J; Romero MR; Lozano E; Anadon C; Macias RI; Serrano MA; Grañé-Boladeras N; Muñoz-Bellvis L; Alvarez L; Sangro B; Pastor-Anglada M; Marin JJ
    Mol Pharm; 2012 Jun; 9(6):1693-704. PubMed ID: 22524153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.